Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma
Phase 2 Completed
21 enrolled 12 charts
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
Phase 2 Completed
35 enrolled 13 charts
Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma
Phase 2 Completed
30 enrolled 12 charts
NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
Phase 2 Completed
25 enrolled 16 charts
Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
Phase 2 Completed
50 enrolled
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Phase 2 Completed
78 enrolled 11 charts
Dalteparin and Radiation Therapy in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme
Phase 2 Completed
45 enrolled
High-Dose Methotrexate and Leucovorin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 2 Completed
36 enrolled
Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas
Phase 2 Completed
118 enrolled 8 charts
Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Phase 2 Completed
182 enrolled 19 charts
Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma
Phase 2 Completed
261 enrolled 10 charts
Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma
Phase 2 Completed
80 enrolled 11 charts
Antineoplaston Therapy in Treating Children With Brain Tumors
Phase 2 Completed
34 enrolled 6 charts
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
Phase 2 Completed
178 enrolled 23 charts
Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors
Phase 2 Completed
54 enrolled 14 charts
Imaging Procedure Using ALA in Finding Residual Tumor in Grade IV Malignant Astrocytoma
Phase 2 Completed
73 enrolled
Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor
Phase 2 Completed
68 enrolled
Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma
Phase 2 Completed
18 enrolled
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
Phase 2 Completed
38 enrolled 53 charts
CAPTIVE
Phase 2 Completed
49 enrolled
BBP
Phase 2 Completed
68 enrolled 11 charts
Radiation Therapy Followed by Carmustine in Treating Patients Who Have Supratentorial Glioblastoma Multiforme
Phase 2 Completed
80 enrolled
Radiation Therapy and Tamoxifen in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme
Phase 2 Completed
77 enrolled
Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Phase 2 Completed
70 enrolled 18 charts
Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Phase 2 Completed
24 enrolled 10 charts
Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma
Phase 2 Completed
7 enrolled 4 charts
SarCNU in Treating Patients With Recurrent Malignant Glioma
Phase 2 Completed
10 enrolled
ReACT
Phase 2 Completed
127 enrolled
Bevacizumab in Treating Patients With Recurrent or Progressive Glioma
Phase 2 Completed
55 enrolled 10 charts
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase 2 Completed
144 enrolled 14 charts
Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase 2 Completed
64 enrolled 12 charts
MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 2 Completed
50 enrolled 16 charts
TAVAREC
Phase 2 Completed
155 enrolled
Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Phase 2 Completed
115 enrolled 11 charts
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
Phase 2 Completed
123 enrolled 16 charts
GW572016 to Treat Recurrent Malignant Brain Tumors
Phase 2 Completed
9 enrolled
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
Phase 2 Completed
82 enrolled
Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor
Phase 2 Completed
44 enrolled
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
Phase 2 Completed
105 enrolled
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase 2 Completed
54 enrolled 8 charts
Boron Neutron Capture Therapy, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 2 Completed
32 enrolled
Temozolomide in Treating Patients With Recurrent High-Grade Glioma
Phase 2 Completed
60 enrolled 9 charts
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
Phase 2 Completed
80 enrolled 15 charts
Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
Phase 2 Completed
33 enrolled 14 charts
Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma
Phase 2 Completed
59 enrolled 8 charts
Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors
Phase 2 Completed
66 enrolled 8 charts
Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
Phase 2 Completed
56 enrolled 9 charts
Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme
Phase 2 Completed
110 enrolled
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
Phase 2 Completed
Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 2 Completed